ReviewTherapeutic delivery2013
Therapeutic nanomedicine for brain cancer.
Review in Therapeutic delivery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.Nanomaterials (Basel, Switzerland) · 2026Review
- Linear Polyethyleneimine-Coated Gold Nanoparticles as a Platform for Central Nervous System Targeting.Polymers · 2026Article
- Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025Review
- Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.Therapeutic delivery · 2025Review
- Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Therapeutic delivery · 2025Review
- Nanomedicine in Management of Cerebral Infarction and Brain Cancer: Role of Inflammation.Current medicinal chemistry · 2025Review
- Advances in nano-delivery of phytochemicals for glioblastoma treatment.Discover nano · 2024Review
- Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.Medical oncology (Northwood, London, England) · 2024Review
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- Cyclodextrin Nanosponges: A Revolutionary Drug Delivery Strategy.Pharmaceutical nanotechnology · 2024Review
- Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders.Molecular diagnosis & therapy · 2023Review
- Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).Cancers · 2023Review
- Nano-inspired smart medicines targeting brain cancer: diagnosis and treatment.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023Review
- Review
- Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors.International journal of molecular sciences · 2021Review
- Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
- Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review.Biomedicines · 2021Review
- Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.AAPS PharmSciTech · 2021Review
- Therapeutic potential ofAmerican journal of neurodegenerative disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Malignant brain cancer treatment is limited by a number of barriers, including the blood-brain barrier, transport within the brain interstitium, difficulties in delivering therapeutics specifically to tumor cells, the highly invasive quality of gliomas and drug resistance. As a result, the prognosis for patients with high-grade gliomas is poor and has improved little in recent years. Nanomedicine approaches have been developed in the laboratory, with some technologies being translated to the clinic, in order to address these needs. This review discusses the obstacles to effective treatment that are currently faced in the field, as well as various nanomedicine techniques that have been used or are being explored to overcome them, with a focus on liposomal and polymeric nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.